Drug intelligence / Profile preview

SOT-107

Development stage: Preclinical
Administration: Intravenous

Overview

SOT-107 is a drug identified as a potential therapeutic agent that targets Platelet-derived growth factor receptor beta (PDGFRB) and Kinase insert domain receptor (KDR). These targets are receptor tyrosine kinases involved in cell growth, proliferation, and angiogenesis, making them relevant in various diseases, including cancer. The drug's activity was noted in the context of glioma research, where it was found to target these specific receptors.

Targets

PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on SOT-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOT-107.

Explore the full profile